ClinicalTrials.gg
CompletedNCT07391358BETA-DAPTUpdated Nov 12, 2026

DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid

An interventional study of Patient decision aid to support shared decision-making between patients and clinicians in Acute Coronary Syndrome, sponsored by Montreal Heart Institute. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Montreal Heart Institute · Not applicable, Interventional, and Other

How we know

Updated Nov 12, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 104 studies in Acute Coronary Syndrome with a site in Canada — 9 open to participants now, 13 under way, 4 of them phase 3. Acute Coronary Syndrome · Canada.

Enrollment
88th of 90
10 · median 504
Started
2026
with 1 other
No phase
27 of 104
3 open now
Registered
101st of 104
by date
Lead sponsor
4 of 104
Montreal Heart Institute

Among the 104 studies in Acute Coronary Syndrome with a site in Canada, this one is the 88th largest by enrollment of the 90 interventional ones that give a count, is one of 2 that started in 2026, is one of 27 with no phase, and was the 101st registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

9 of the 104 studies in Acute Coronary Syndrome with a site in Canada are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Acute Coronary Syndrome with a site in Canada, or all of them as a file.
02

Study summary

Among patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI) and stent implantation, 17.5% are both at high bleeding risk (HBR) and have undergone complex PCI, which also places them at high thrombotic risk. In this population, several dual antiplatelet therapy (DAPT) strategies may be considered: (1) de-escalation of DAPT intensity after 1 to 3 months (switch from ticagrelor/prasugrel to clopidogrel), (2) shortening DAPT duration to 1 to 3 months followed by antiplatelet monotherapy, (3) 12-month clopidogrel-based DAPT, and (4) 12-month ticagrelor/prasugrel-based DAPT. Selecting the most appropriate DAPT strategy in this dual-risk context is complex, and clinical trial evidence is limited for this specific subgroup. In the absence of clear guideline recommendations to support decision-making for patients facing both elevated bleeding and thrombotic risks, structured shared decision-making support is needed.

In this context, within research project 2025-3499 conducted with pharmacy residents, we developed a patient decision aid (PDA) designed to support shared decision-making by helping patients understand their risks, available options, and potential consequences, so they can express their preferences regarding antiplatelet therapy. The PDA aims to facilitate shared decisions by improving patients' understanding of benefits and harms and aligning choices with patient values. A preliminary version of the tool has already undergone alpha testing with a small group of internal users (physicians, pharmacists, and patient partners). The next step is beta testing, that is, real-world testing with the target population and clinicians to evaluate usability and acceptability in routine practice.

03

Conditions studied

  • Acute Coronary Syndrome

Keywords

  • High bleeding risk
  • Complex percutaneous coronary intervention
  • Double antiplatelet therapy
  • Patient decision aid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (Patients)

  • Adults aged 18 years or older
  • Hospitalized on the coronary care unit ward at the Montreal Heart Institute (MHI)
  • Acute coronary syndrome (ACS) during the current episode of care, treated with PCI and placement of one or more coronary stents
  • High bleeding risk based on PRECISE-HBR score and high thrombotic risk, with both risks considered of comparable clinical importance by the treating medical team

Inclusion Criteria (Clinicians)

- Clinicians working in the MHI coronary care unit (cardiologists, medical residents, nurse practitioners, or pharmacists) who use the patient decision aid with one or more study participants

Exclusion Criteria (Patients)

  • Receiving therapeutic anticoagulation
  • Planned cardiac surgery during the same episode of care
  • Prior history of coronary stent thrombosis
  • Antiphospholipid syndrome or known thrombophilia
  • Unable to participate in shared decision-making
  • Unable to understand spoken and written French or English
  • Concurrent participation in another study (followed within another research protocol)
  • Transferred from another center for reasons other than coronary angiography at MHI and expected to return to the referring center for ongoing care (i.e., "fly-in/fly-out" patients)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Other
    High bleeding risk patients treated with complex PCI in the context of ACS

    The intervention is the use of the Patient Decision Aid (PDA) to support shared decision-making between patients and clinicians after PCI, assessed using questionnaires capturing multiple dimensions of decision quality. No pharmacologic treatment is administered as part of the study; exposure consists solely of complete use of the PDA according to the protocol. The study includes a single pre-post group, no interim analyses are planned given the limited project duration, and a single beta-testing phase will be conducted.

    Other: Patient decision aid to support shared decision-making between patients and clinicians

Interventions

  • OtherPatient decision aid to support shared decision-making between patients and clinicians

    Patient decision aid to support shared decision-making between patients and clinicians by helping patients understand their risks, available options, and potential consequences, so they can express their preferences regarding antiplatelet therapy.

06

What researchers measure

Primary outcomes

  1. Change in Decisional Conflict (DCS-LL) After Use of the Patient Decision Aid (PDA)

    Change in total score on the low-literacy Decisional Conflict Scale (DCS-LL; Ottawa Hospital Research Institute), comparing pre-PDA vs post-PDA completion. Lower scores indicate less decisional conflict.

    Time frame: Baseline (pre-PDA, Day 0) and immediately post-PDA completion (Day 0, index hospitalization).

Secondary outcomes

  1. Change in Antiplatelet Strategy Knowledge Score After PDA Use

    Change in total score on an adapted OHRI knowledge questionnaire assessing understanding of bleeding and thrombotic risks and DAPT options, comparing pre-PDA vs post-PDA completion.

    Time frame: Baseline (pre-PDA, Day 0) and immediately post-PDA completion (Day 0, index hospitalization).

  2. Preparation for Decision-Making (PrepDM) Score After PDA Use

    Total score on the Preparation for Decision Making (PrepDM; OHRI) questionnaire completed after PDA use. Higher scores indicate greater perceived preparedness to make a decision with the clinician.

    Time frame: Immediately post-PDA completion (Day 0, index hospitalization).

  3. Patient Acceptability Score of the PDA in Routine Clinical Use

    Total score on an OHRI acceptability questionnaire completed after PDA use, reflecting perceived relevance, clarity, length, and overall acceptability in the clinical setting.

    Time frame: Immediately post-PDA completion (Day 0, index hospitalization).

  4. Patient Refusal Rate to Use the PDA and Reasons for Refusal

    Number and proportion of eligible patients who personally refuse participation/PDA use, and categorization of documented reasons for refusal (e.g., not interested, too tired, overwhelmed, language barriers, time constraints).

    Time frame: Pre-intervention (at the time of the consent request, prior to PDA delivery, during the index hospitalization).

  5. Agreement Between Patient-Preferred Antiplatelet Strategy and Strategy Prescribed at Hospital Discharge

    Proportion of agreement between (a) the antiplatelet strategy preferred by the patient as identified through the PDA and (b) the antiplatelet strategy documented on the discharge prescription/orders.

    Time frame: At hospital discharge (index hospitalization), comparing the patient preference recorded immediately after PDA completion with the antiplatelet strategy on the discharge prescription/orders (also post-PDA completion).

  6. Clinician Usability of the PDA (French System Usability Scale, F-SUS)

    Total score on the French System Usability Scale (F-SUS) completed by clinicians after using the PDA with an included patient in routine clinical care. Higher scores indicate better usability.

    Time frame: Day 0 (immediately after PDA use with an included patient)

  7. Clinician Refusal Rate to Use the PDA and Reasons for Non-Use

    Number and proportion of eligible patient encounters in which the clinician declines to use the PDA when asked, along with categorization of documented reasons (e.g., time constraints, clinical instability, workflow barriers, clinician preference).

    Time frame: Pre-intervention (at the time the clinician is asked whether it is appropriate to approach the patient and offer the PDA, prior to patient approach and prior to PDA delivery, during the index hospitalization).

Other outcomes

  1. Exploratory Subgroup Effects on Decisional Conflict Scores Low Litteracy (DCS-LL) Questionnaire

    Exploratory assessment of whether changes in DCS-LL differ by prespecified characteristics: age (\<70 vs ≥70 years), sex (male vs female), mother tongue (French vs English), education level (university vs lower) and prior percutaneous intervention with stent (yes or no). Analyses are descriptive/exploratory.

    Time frame: Baseline (pre-PDA, Day 0) and immediately post-PDA completion (Day 0, index hospitalization).

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2026 to primary completion in Sep 2026, 7 months.

Of 213 non-industry interventional studies with no phase under Acute Coronary Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 46. This study's 7 months is below that.

Counting every sponsor, half of 228 studies reached it within 34 months; a quarter within 17 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Aug 2026 → Sep 2026 and completion Dec 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2026
First posted
Feb 5, 2026
StartActual
Feb 1, 2026
Primary completionActual
Sep 30, 2026was Aug 2026
CompletionActual
Sep 30, 2026was Dec 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Nov 12, 2026
Primary completion
Aug 31, 2026→Sep 30, 2026 (actual)
Nov 12, 2026
Study completion
Dec 31, 2026→Sep 30, 2026 (actual)
Nov 12, 2026
Enrollment
26 (estimated)→10 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Not yet recruiting→Completed
    Primary completion Aug 31, 2026→Sep 30, 2026 (now actual)
    Study completion Dec 31, 2026→Sep 30, 2026 (now actual)
    Enrollment 26 (estimated)→10 (actual)
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07391358
Responsible party
Julien Quang Le Van (Pharmacist, Montreal Heart Institute) — Principal investigator
First posted
Feb 5, 2026
Start date
Feb 1, 2026
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion